NanoString® is a new optical technology that directly counts molecules with zeptomole sensitivity and digital precision. It has many advantages over PCR and RNAseq for detecting DNA, mRNA, miRNA, lncRNA, gene fusions and protein molecules (and combinations thereof). Many applications are enzyme-free so, for example, PCR and RT steps are are not required for gene expression analysis. It can also multiplex up to 800 targets in only 4 simple pipetting steps. Sample flexibility is a hall-mark of the technology and sample input can range from total RNA, single cells, raw cell and tissue lysate, blood, FFPE tissue, etc, derived from any living species. There are already 14 nanoString systems in Australia and New Zealand and uptake of this new technology has been unprecedented around the world.
Peer-reviewed nanoString publications are growing exponentially (currently over 850, you’ll find a list here1). The technology is ideal for translational research and diagnostic assay development, exemplified by nanoString's own FDA-cleared Prosigna™ 2 breast cancer assay, now TGA-approved and available in Australia.